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1109-134 Clinical Features of Mixed Physiology of Constriction 
and Restriction
Hirotsugu Yamada, Tomotsugu Tabata, Jeanne K. Drinko, Susan E. Jasper, Michael S. 
Lauer, James D. Thomas, Allan L. Klein, Cleveland Clinic Foundation, Cleveland, OH
Background: Patients with mixed physiology of constriction and restriction have been
reported, but their long-term survival has not been well documented.
Methods: Study subjects consisted of 38 patients (57 ± 14 yrs, 8 female, 30 male) who
were diagnosed as having mixed physiology based on echocardiography, MRI (or CT),
cardiac catheterization, endomyocardial biopsy and/or surgical findings. We evaluated
their echocardiographic, clinical features and calculated Kaplan-Meier survival curve to
compare with that in patients with pure constriction.
Results: Prior radiation therapy was the most frequent (50%) cause of mixed physiology
followed by coronary artery bypass graft without prior radiation and heart transplantation.
The respiratory variation of peak early diastolic transmitral flow velocity was 10.7% in
patients with sinus rhythm, 18.1% in patients with atrial arrhythmia. Pericardial thickening
was localized in 29 patients. All-cause 5-year mortality was 40 % and unrelated to age,
etiology, left ventricular systolic function and therapeutic course. There was a significant
difference between the survival rates in patients with mixed physiology and in 133
patients with pure constriction (Figure).
Conclusions: Because of the high mortality in mixed disease, discrimination of this
entity from pure constriction is important. Echocardiography is helpful noninvasive tech-
nique in diagnosis and understanding the physiology of the patients with mixed constric-
tion and restriction.
ORAL CONTRIBUTIONS
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8:30 a.m.
834-1 Vascular and Autonomic Dysfunction in the 
Asymptomatic Stage of Chagas’s Disease
Juan C. Guzman, Hernando Leon, Ronald G. Garcia, Juan P. Casas, Federico A. Silva, 
Patricio Lopez-Jaramillo, Carlos A. Morillo, Fundacion Cardiovascular de Colombia, 
Floridablanca, Colombia
Background: Chagas’ Disease (ChD) is associated with impaired cardiac automic func-
tion (CAF) and altered peripheral endothelial vascular reactivity. The relationship
between these two alterations has not been explored in the early asymptomatic stage of
ChD.
Methods: 22 asymptomatic seropositive subjects to ChD were compared with 19 asymp-
tomatic seronegative subjects (CON). All patients had a noninvasive assessment of CAF:
deep breathing test (DBT), arterial baroreflex (BRS) and lower body negative pressure @
-10mmHg (LBNP) and endothelial function measured by forearm blood flow (FBF),
peripheral vascular resistance (PVR) and venous occlusion plethysmography with vaso-
active substances: nitroglycerine (NTG) and acetylcholine (Ach)
Results No significant differences were found between the two groups at baseline. A sig-
nificant reduction was found (p<0.01) in the BRS 17.6±8.3 vs 28.3±14.1 and DBT 11.0
±5.7 vs 17.2 ±7.2 in ChD patients vs CON. Significant differences were found between
ChD vs CON in FBF at rest;1.4±0.4vs.2.3±0.7 (p<0.001) and during
LBNP;1.0±0.3vs.1.5±0.6. Moreover significant differences were found in PVR at rest
65.3±20.2 vs 41.1±15.4 (p<0.05), LBNP 103.7±26.6 vs 71.8±43.01. ChD group had
lower response than CON in terms of percentage of change of FBF in response to the
infusion of incremental dosages of NTG: 8 nmoll/min 49.7±34.5 vs. 82.7±58.0; 16 nmol/
min 62.2±43.5 vs 159.6±83.6; 34 nmol/min 77.9±54.8 vs 197.13±10.8.5 and with Ach 25
nmol/min 88.4±57 vs 172.8±104; 50 nmol/min 103.1±46 vs 172.7±128; 100 nmol/min
125.3±93 vs 210.5±123.
Conclusion: Asymptomatic ChD patients have early impairment of vascular endothelial
function mediated by an increase in efferent sympathetic activity that leads to elevated
PVR. These findings may be related to alterations in the endothelial production of nitric
oxide and lower vascular smooth muscle response to NO. These alterations may play a
role in precipitating and maintaining the progressive damage of myocardial microvascula-
ture and contribute to the development and progression of the Chagasic cardiomyopathy.
(Colciencias Grant: 6566-04-10268)
8:45 a.m.
834-2 Clonal T-Cell-Receptor Composition Is Not Associated 
With Enteroviral or Adenoviral Infection in Dilated 
Cardiomyopathy: Implications for the Pathogenesis of 
Dilated Cardiomyopathy
Michel Noutsias, Michael Hummel, Chalid Assaf, Harald Stein, Uwe Kuhl, Heinz Peter 
Schultheiss, Matthias Pauschinger, Charité - Campus Benjamin Franklin, Berlin, 
Germany
Background: Autoimmunity, resulting from molecular mimicry between viral and cryptic
cardiac antigens, is postulated for the pathogenesis of dilated cardiomyopathy (DCM).
Autoimmunity targeting distinct antigens evokes expansion of specifically reactive T-cell
clones infiltrating the target tissue, which can also result from chronic presentation of for-
eign (e.g. viral) antigens.
Methods: DNA extracted from explanted DCM hearts (n=17, 1 female; 49±13 years;
LVEF: 18±5%) were investigated by a family specific PCR for the Vß-N-Dß-N-Jß-region
of the TCR gene and GeneScan-analysis for clonal TCR rearrangement. Non-DCM-
hearts (ischaemic cardiomyopathy: n=2, valvular heart disease: n=3, donor hearts: n=3)
served as controls. The TCR-PCR-products analyzed by high-resolution fragment analy-
sis (GeneScan), displayed a Gaussian-like distribution profiles in polyclonal and single
dominant peaks in monoclonal T-cell populations. Clonal TCR-ß PCR-products were
directly sequenced. Enteroviral and adenoviral genome was amplified by PCR.
Results: The GeneScan analysis of the TCR-ß PCR-products demonstrated a clonal T-
cell population in n=9/17 (53%) of the DCM hearts. In contrast, exclusively polyclonal
composition of the TCR-Vß PCR-products were obtained from the non-DCM hearts.
Sequence analysis of the clonal TCR-Vß PCR-products from the n=9 DCM hearts deter-
mined Vß19.01 in n=6 cases (67%), and Vß6-1.01, Vß6-3.01 and Vß10-3.04 in each of
the remaining cases. Clonal TCR-composition was not significantly (p>0.05) associated
with PCR amplification of viral genome.
Conclusions: Clonal TCR rearrangement is exclusively present in DCM but not in fur-
ther cardiomyopathies. The clear predominance of Vß19.01 family T-cell clones in DCM
indicates that these TCR clones target specific antigens. Our results are consistent with
the autoimmune hypothesis of DCM, since entero- or adenoviral persistence are not sig-
nificantly associated with a specific clonal TCR rearrangement. Eventually, a TCR-based
immunotherapy in DCM (e.g. with anti-TCR antibodies or DNA vaccines) might be a fea-
sible therapeutic option in DCM with clonal TCR-composition.
9:00 a.m.
834-3 Impaired Hyperaemic Myocardial Blood Flow Is Related 
to Systolic Function in Idiopathic Dilated 
Cardiomyopathy
Paul Knaapen, MWJ Götte, JJM Zwanenburg, JT Marcus, P. A. Dijkmans, WG van 
Dockum, CA Visser, AC van Rossum, AA Lammertsma, FC Visser, VU University 
Medical Center, Amsterdam, The Netherlands
Aim. Hyperaemic myocardial blood flow is impaired in patients with idiopathic dilated car-
diomyopathy (DCM). The degree of impairment is related to diastolic dysfunction and
prognosis. This study was conducted to evaluate the relation between hyperaemic myo-
cardial blood flow and systolic function in patients with DCM.
Materials & Methods. Patients with advanced stage of idiopathic dilated cardiomyopathy
(NYHA III or IV; EF<35%) and healthy control subjects were studied. Myocardial blood
flow (MBF) was determined by positron emission tomography (PET) using 15O-labelled
water under baseline conditions and during pharmacologically induced stress. MR tissue
tagging was performed for quantification of regional myocardial function. End systolic cir-
cumferential shortening (ESCS) was calculated using the Harmonic Phase (HARP)
method.
Results. Ten patients with DCM (mean age 54±10 yrs, 5 male) and 7 control subjects
(mean age 28±3 yrs, 6 male) were studied. Mean rest MBF was similar for DCM and con-
trols (0.91±0.33 vs. 0.97±0.21 ml/min/g, respectively, p=NS). Hyperaemic MBF and
ESCS were reduced in DCM (2.23±1.01 ml/min/g and 6.1±2.4%, respectively) compared
to controls (4.09±0.80 ml/min/g and 15.2±1.3%, respectively, p<0.01). There was a sig-
nificant correlation between stress MBF and ESCS in DCM (r=0.89, p<0.01). No correla-
tion was present between rest MBF and systolic function in DCM. 
Conclusions. The combination of PET and MRI offers a unique opportunity to quantita-
tively assess global and regional perfusion and function. In patients with advanced stage
of DCM, the degree of impaired hyperaemic blood flow is related to systolic dysfunction.
9:15 a.m.
834-4 Coronary Vasodilator Responses Are Impaired 
Independent of Nitric Oxide and Endothelial Function in 
Conscious Dogs With Dilated Cardiomyopathy
Lazaros A. Nikolaidis, Aaron Doverspike, Teresa Hentosz, Rhonda Huerbin, Richard P. 
Shannon, Allegheny General Hospital, Pittsburgh, PA
Background: Dilated cardiomyopathy (DCM) has been associated with nitric oxide (NO)
deficiency and endothelial dysfunction, resulting in depressed systemic and coronary
vasodilator responses to endothelium-dependent challenge. However, it remains contro-
versial as to whether endothelium-independent vasomotor function is preserved in DCM,
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particularly in the coronary circulation. We have shown previously that intrinsic smooth
muscle tone in coronary vessels in DCM is depressed, but the functional significance of
this observation in vivo is unknown.
Methods: We studied the responses of the systemic and coronary circulation to a variety
of vasodilators in conscious dogs with pacing-induced DCM (240 min-1, 29±4 days). The
dogs received graded IV infusions of the endothelium-dependent acetylcholine (ACH,
0.25-5 µg/kg, n=18), the c-GMP dependent NO-donor nitroglycerin (NTG, 30-240 µg,
n=18), the predominantly endothelium-independent adenosine (ADO, 0.5-5 µmol/kg,
n=9), the β-adrenergic c-AMP dependent agonist isoproterenol (ISO, 0.05-0.4 µg/kg,
n=14) and the calcium channel antagonist nicardipine (NIC, 0.3-10 µmol/kg, n=6) in con-
trol (C) and in severe DCM.
Results: Systemic responses were impaired to ACH but preserved to all other vasodila-
tors in DCM. However, coronary flow (CBF) and vasodilator responses (CVR) were sig-
nificantly (p< 0.05) depressed to all agonists when equivalent doses were compared.
(Peak CBF responses, C vs DCM: ACH: 221±14% vs 160±11%, NTG: 220±17% vs
138±9%, ADO: 635±74% vs 413±65%, NIC: 338±59% vs 115±23%, ISO: 219±19% vs
87±21%. Peak CVR responses, C vs DCM: ACH: -77±1% vs -69±1%, NTG: -75±1% vs -
62±2%, ADO: -88±1% vs -77±3%, NIC: -79±2% vs -63±4%, ISO: -67±2% vs -48±5%).
This generalized impairment in coronary vasodilator responses persisted after controlling
for heart rate differences or changes in mean arterial pressure.
Conclusions: In contrast to systemic vasodilator responses, coronary vasodilation in
DCM is impaired to a multitude of agonists, dependent or independent of NO or second
messenger mechanisms. This implies structural or distal signaling defects unique to the
coronary vascular smooth muscle in DCM.
9:30 a.m.
834-5 Outcomes of Peripartum Cardiomyopathy in the Current 
Era of Heart Failure Management
José A. Tallaj, Saema Mirza, Barry K. Rayburn, Laura J. Pinderski, Raymond L. Benza, 
Brian A. Foley, Salpy Pamboukian, Robert C. Bourge, University of Alabama at 
Birmingham, Birmingham, AL, Birmingham VA Medical Center, Birmingham, AL
Background: Patients with peripartum cardiomyopathy (PPC) have a better prognosis
than other forms of cardiomyopathy. However, historical studies showed that 40 to 50% of
patients with PPC do not have a meaningful recovery or experienced a significant deteri-
oration in their cardiac function. These studies were done before the current era of heart
failure management. We report the University of Alabama at Birmingham’s experience
with this form of cardiomyopathy.
Methods and Results: Thirty-seven patients were referred to our program with peripar-
tum cardiomyopathy between January 1, 1990 and December 31, 2002. The data was
extracted from the clinical charts. The age at diagnosis was 28±6.6 years, and on aver-
age patients were 33 days postpartum (range 60 days pre-180 days post-partum).
Eighty-one percent were NYHA class III or IV. The mean LVEDD was 57.9±10.0 mm and
the LVEF was 23.5±11.5%. Thirty-two (87%) were treated with ACE inhibitors, 9 (25%)
with angiotensin receptor blockers and 17 (46%) with beta-blockers. In addition they were
also treated with digoxin (76%), diuretics (89%), spironolactone (33%), nitrates (6%) and
warfarin (41%).
Patients were followed for an average of 28 (range 1-94) months. Four patients were
transplanted, 1 died and 1 was lost to follow-up. The NYHA class improved significantly
(P=0.007). More importantly, the NYHA class improved in all but the patients who died or
were transplanted or lost to follow-up. Of the survivals or not transplanted or lost to fol-
low-up, 25/31 (90%) were NYHA class I-II and none was NYHA class IV. Thirty-one
patients had follow-up echocardiograms in our institution. Overall, the LVEF improved
significantly to 40.3±16.4% (p<0.001), as well as the LVEDD (52.8±8.8 mm, p=0.007).
Seventy-two percent of the patients had a significant improvement in the LVEF to > 40%,
and 42% of patients normalized their LVEF. There was no difference in NYHA class,
LVEF or transplant/death rates in patients who were treated with beta-blockers compared
to whose who were not.
Conclusion: The prognosis of PPC appears to be better than previously reported. Trans-
plantation or more invasive therapies should be reserved for those patients who fail med-
ical therapy.
9:45 a.m.
834-6 Identification of Cardiac Sarcoidosis From the Patients 
Presenting as Unexplained Heart Failure and 
Cardiomyopathies
Osamu Yokoseki, Yoshikazu Yazaki, Kaoru Kogashi, Takeshi Hanaoka, Yuichi Kai, 
Osamu KInoshita, Minoru Hongo, Keishi Kubo, Morie Sekiguchi, Shinshu University, 
Matsumoto, Japan
Background: Diagnosis of cardiac sarcoidosis (CS) is usually confirmed during the fol-
low-up of extra-cardiac sarcoidosis. However, the diagnosis is often difficult when CS
patients show heart failure as the first manifestation without evidence of involvement of
other organs because endomyocardial biopsy frequently fails to reveal non-caseating
epithelioid granuloma. Majority of these patients are diagnosed as idiopathic dilated car-
diomyopathy (DCM). Methods: To characterize CS patients presenting as unexplained
heart failure (CS-HF), we reviewed 30 consecutive CS patients diagnosed between 1987
and 2002 and identified 11 CS-HF patients. Clinical findings and outcome of the CS-HF
were compared to those of 123 DCM patients diagnosed at the same period. Results:
Abnormal accumulation of gallium-67 in the heart or extra-cardiac tissue was the first
clue to suspect CS in 7 of the 8 CS-HF who underwent the whole body gallium-67 scan.
Granulomas were confirmed from the heart in 5 patients, lymph nodes in 4, skin in 1 and
skeletal muscle in 1. The CS-HF showed higher incidence of female (70% vs. 22%, p<
0.001), complete atrioventricular block (70% vs. 0%, p<0.0001) and sustained ventricular
tachycardia (40% vs. 9%, p< 0.05), and lower cardiac index (2.0±0.4 l/min/m2 vs. 2.5±0.5
l/min/m2, p< 0.05) and left ventricular dimension (58±11 mm vs. 68±8 mm, p<0.05) as
compared with DCM patients. During a mean follow-up of 80 months, 6 CS-HF died sud-
denly or of refractory heart failure. Although 10 of the 11 were treated with corticoster-
oids, survival rate was significantly worse in CS-HF than DCM (40% vs. 72%, p<0.001).
Conclusions: CS-HF had different clinical features and outcomes as compared with
DCM. Understanding these features and comprehensive examinations including whole
body gallium-67 scan and biopsies from the extra-cardiac tissue are useful for the diag-
nosis of CS patients presenting as unexplained heart failure and cardiomyopathies.
ORAL CONTRIBUTIONS
835 Heart Failure: Clinical Trials
Tuesday, March 09, 2004, 8:30 a.m.-10:00 a.m.
Morial Convention Center, Room 257
8:30 a.m.
835-1 A Comparison of Adverse Events Occurring With 
Carvedilol or Metoprolol in the Treatment of Heart 
Failure: Results From COMET
Philip A. Poole-Wilson, Karl Swedberg, John G. Cleland, Andrea Di Lenarda, Peter 
Hanrath, Beatrix Lutiger, Michel Komajda, Marco Metra, Willem J. Remme, Armin 
Scherhag, Andrew Charlesworth, Christian Torp-Pedersen, For the COMET 
investigators, National Heart and Lung Institute, London, United Kingdom, Sahlgrenska 
University Hospital, Göteborg, Sweden
Background: In COMET carvedilol (25 mg bid) was shown to reduce mortality compared
to metoprolol (IR 50 mg bid) (512 deaths/1511 versus 600/1518, p=0.0017) in the treat-
ment of heart failure with a mean follow-up of 57.9 months. Adverse events would be
expected to reflect this advantageous outcome. The alpha-1 and beta-2-blocking effects
of carvedilol, which possibly contributed to its survival advantage, are expected to be
reflected in the adverse events profile.
Methods: 3029 patients with left ventricular systolic dysfunction and NYHA class II to IV
were randomised to double-blind study therapy. Patients were seen every four months
over a period of 47 to 71 months. Adverse events as reported by the investigator were
recorded on the case record form and analysed centrally.
Results: Of 1511 patients allocated to carvedilol 93.6% experienced an adverse event
and 73.9% a cardiovascular adverse event. Of 1518 patients allocated metoprolol the fig-
ures were 95.9% and 75.8%. Adverse event reports of sudden death (8.9% versus
12.1%), myocardial infarction (4.6% versus 6.3%), unstable angina (3.8% versus 5.1 %)
and stroke (3.5% versus 4.3%) were less common with carvedilol. Heart failure (42.6%
versus 44.9%), dyspnoea (9.7% versus 11.2%) and peripheral oedema (2.6% versus
3.7%) occurred less frequently with carvedilol. No consistent differences existed with
regard to bradycardia or heart block. Hypotension (14.2% versus 10.5%), dizziness
(12.4% versus 11.7%) and syncope 8.2% versus 6.3%) were commoner with carvedilol.
Diabetes (11.1% versus 12.5%) and hypokalaemia (2.0% versus 3.2%) were less com-
mon with carvedilol. The incidence of bronchospasm (0.7% versus 0.4%) and asthma
(0.5% versus 0.3%) was very low in both groups.
These differences do not take account of the fact that because of the greater mortality
with metoprolol more patients in the carvedilol group were available to experience
adverse events.
Conclusion: The lower number of adverse cardiovascular events with carvedilol reflects
the beneficial effect on mortality. Metabolic and haemodynamic adverse events are com-
patible with the known different properties of these two beta-blockers.
8:45 a.m.
835-2 Carvedilol Better Protects Against Vascular Events 
Than Metoprolol in Heart Failure: Results From COMET 
Willem J. Remme, John G. Cleland, Andrea Di Lenarda, Peter Hanrath, Beatrix Lutiger, 
Michel Komajda, Marco Metra, Armin Scherhag, Andrew Charlesworth, Christian Torp-
Pedersen, For the COMET Investigators, STICARES - Cardiovascular Institute, Rhoon, 
The Netherlands, Bispebjerg Hospital, Copenhagen, Denmark
Background: In the COMET study carvedilol (C) had a significantly greater benefit on
survival than metoprolol (M) in patients with NYHA class II-IV heart failure (HF), with a
20% reduction for cardiovascular (CV) mortality (RR 0.80 ;95% CI 0.7-0.9, p=0.0004).
Here, we report the differentiation of CV death and the possible contribution of vascular
event reduction to the beneficial effect of carvedilol.
Methods: 3029 patients with NYHA class II-IV HF, due to ischemic (51-54%) or idio-
pathic cardiomyopathy (44%) were randomized to C (n=1511) or M (n=1518) and fol-
lowed-up double-blind for 58 months. Baseline characteristics and primary outcomes
have been reported. Mode of deaths was adjudicated centrally. CV death included sud-
den, worsening HF, stroke and other CV death. Hospitalizations for myocardial infarctions
were based on pre-specified criteria. Data provided are in the intention-to-treat popula-
tion.
Results: Sudden death and death due to worsening HF were reduced in C compared to
M (RR 0.81, CI 0.68-0.97 p=0.02, and RR 0.83, CI 0.67-1.02 p=0.07 respectively).
Myocardial infarctions were reported in 69 C and 94 M patients (RR 0.71, CI 0.52-0.97,
p=0.03). Of these, 21 and 36 lead to death in C and M respectively. CV death or non-fatal
myocardial infarction combined were reduced by 19% in C, compared to M (RR 0.81, CI
0.72-0.92, p=0.0007). A stroke occurred in 65 C and 80 M patients (RR 0.79, CI 0.57-
1.10). C significantly reduced stroke deaths, 13 C versus 38 M (RR 0.33, CI 0.18-0.62,
